What the Peer-Reviewed Record Establishes
The primary research record in Adjuvant Therapies for Recurrence Prevention is stratified by study design so that meta-analyses and replicated randomised controlled trials (T1–T2) carry greater epistemic weight than observational cohorts (T3–T4) or preclinical laboratory work (T5). Leading graded findings establish the core empirical baseline: [T1] Postoperative use of the levonorgestrel-releasing intrauterine system (LNG-IUS) is associated with a reduction in the recurrence rate of endometrial polyps compared to observation-only cohorts. [5][12] [T3] Risk factors for recurrence of endometrial polyps include age, body mass index, polyp size, and endometrial thickening. [32][35]
Further clinical and mechanistic stratification across the literature demonstrates: [T3] There is no statistically significant difference in endometrial polyp recurrence rates among women treated with short-term (2-3 months) postoperative estrogen-progestin sequential therapy, combined oral contraceptives, or no hormonal therapy following concurrent hysteroscopic adhesiolysis and polypectomy. [1] [T3] Combined oral contraceptives and cyclic progestogens are associated with a reduction in the need for repeat intrauterine interventions following polypectomy. [14][5]
Comparative Evaluation of Levers & Theoretical Models
Within the Tree of Knowledge, this field branches into 3 specialised sub-disciplines: Aromatase Inhibitors and Estrogen Antagonists (Alternative pharmacotherapy targeting local estrogen production and receptor sensitivity in refractory or high-risk recurrence cases); Contraceptives, Oral, Combined (The role of ethinyl estradiol and progestin combinations in stabilizing the endometrium and regulating menstrual cycle dynamics post-polypectomy); Endometrial Hyperplasia and Premalignant Risk (Investigation of whether adjuvant hormonal therapy effectively targets the underlying hyperplasia often comorbid with recurring polyps).
Evolution of the Field, Open Debates & Active Trials
Active scientific debates and unresolved methodological tensions centre on: Conflicting findings exist regarding the efficacy of oral contraceptives and progestogens in preventing recurrence, with some studies showing no significant difference compared to observation, while others suggest reduced need for repeat intervention. (contradiction) Evidence suggesting scissors reduce recurrence compared to graspers relies on single-study data and lacks broad validation. (weak evidence)
Open Questions & Priorities for the Next Research Sweep
Methodological priorities and open empirical questions queued for the next research sweep across Adjuvant Therapies for Recurrence Prevention focus on resolving subgroup effect sizes, causal mechanisms, and long-term outcomes:
- Optimal duration of hormonal adjuvant therapy for recurrence prevention
- Head-to-head trials comparing different hormonal delivery routes (LNG-IUS vs systemic oral)
- Impact of hysteroscopic technique on long-term recurrence beyond 12 months
- Cost-effectiveness of routine hormonal suppression post-polypectomy versus symptom-driven surveillance